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ABSTRACT 
Methicillin resistant Staphylococcus aureus (MRSA) is a potentially 
pathogenic bacterium that poses a serious risk in healthcare settings. MRSA can be 
characterized by a genetic element, known as the staphylococcal cassette 
 8 
chromosome, which harbors the gene responsible for methicillin resistance, mecA. 
MRSA can be classified into two categories: community acquired (CA) and hospital 
acquired (HA). S. aureus strains represent a major health concern due to their 
prevalence in healthcare facilities and their rapidly evolving antibiotic resistance. 
The current study investigated the association between MRSA isolates obtained 
from patients and from the intensive care units in a local hospital. Among the 
bacteria isolated from the neonatal and pediatric intensive care units were 
Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, and members of 
the Micrococcus and Bacillus genera. MRSA isolates were confirmed by a 
combination of mannitol salt agar, CHROM agar, and antibiotic disc diffusion tests. 
Genomic DNA was extracted from the MRSA isolates by multiplex PCR to 
differentiate between CA and HA. We utilized multiple genomic markers to identify 
the mecA gene, differentiate the types of MRSA, and observe if specific toxins were 
present in twenty-five patient samples and eight environmental samples. In patient 
samples type II (HA), type III (HA), and type IVd (CA) were confirmed. In 
environmental samples type III (HA), type IVa (CA), and type V (CA) were 
confirmed. Both patient and environmental samples expressed the mecA gene 
indicative of MRSA. The only correlative genomic marker between patient and 
environmental samples was the type III and mecA gene; however, several isolates 
possessed mecA but did not match any of the types tested. Ongoing research 
involves the examination of over fifty more MRSA isolates, allowing further 
molecular characterization and determination of MRSA exchange in a healthcare 
setting. 
 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1  
Introduction and Background 
1.1 Multi-Drug Resistant Bacteria 
 10 
Antimicrobials were developed by humans to reduce the impact of disease-
causing microbes, with the most common type of antimicrobials being antibiotics. 
Most antibiotics target bacteria.1 Penicillin, the first commercialized antibiotic, was 
discovered in 1928 by Alexander Fleming and began to be distributed to the 
general public in 1945.2 The introduction of Penicillin was extremely useful for 
fighting surgical and wound infections with some referring to it as the “miracle 
drug”.3 Without the use of much needed antibiotics infected patients could 
experience increased recovery time, increased medical expenses, limb removal due 
to tissue necrosis, or even death. Unfortunately, over time certain bacteria 
developed strains that exhibited resistance to penicillin, creating a need for 
different antibiotics.4 Throughout the following years new antibiotics were 
introduced including, but not limited to, tetracycline, erythromycin, methicillin, 
gentamicin, and vancomycin.1 
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Antibiotic Year Antibiotic 
Introduced 
Year Antibiotic 
Resistance Identified 
Penicillin 1943 1965 
Tetracycline 1950 1959 
Erythromycin 1953 1968 
Methicillin 1960 1962 
Gentamicin 1967 1979 
Vancomycin 1972 1988 
Levofloxacin 1996 1996 
 
 
 
 
Antibiotic resistance occurs when bacteria are able to resist the effect of 
drugs- therefore the bacteria are not killed and their growth is not inhibited.1 
Throughout the 21st century antibiotic resistance has emerged to the forefront of 
public healthcare concerns.6 In 2013, according to the Center for Disease Control 
and Prevention, a minimum of 2 million people in the United States experienced 
serious infections due to bacteria resistant to at least one antibiotic used to treat 
those infections, and at least 23,000 people died directly due to antibiotic-resistant 
Table 1.1 A timeline showing the evolution of antibiotic resistance in relation to antibiotic 
introduction.5 
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infections.7 In Europe approximately 400,000 people were infected with multidrug-
resistant bacteria leading to about 25,000 deaths in 2007.8 The growing issue of 
drug resistant bacteria is a global concern that carries many implications and is a 
very complex, multifactorial issue.6 There are various ways bacteria become 
resistant to antibiotics. It is possible for bacteria to “neutralize” an antibiotic by 
changing it in a way that essentially makes it harmless. Another way occurs when 
bacteria change their outer structure preventing the antibiotic from attaching to 
the bacteria it is programmed to kill.9 Overuse and misuse of antibiotics can 
contribute to the development of antibiotic-resistant bacteria. A well-known group 
of drug resistant bacteria are the ESKAPE pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species).10 They are able to “escape” the 
actions of antibiotics and are the leading cause of Healthcare Associated Infections 
(HAIs) throughout the world.10,11 
 
1.2 Staphylococcus aureus  
Staphylococcus aureus was discovered in the 1880s by surgeon Sir 
Alexander Ogston.12 It was found to be a Gram-positive bacterium that is 
responsible for causing a wide range of infections and diseases, varying from minor 
skin infections to post-operative wound infections, necrotizing pneumonia, and 
bacteremia.13,14 S. aureus can express resistance to many antibiotics.15,16 Early on 
the mortality rate for patients infected with S. aureus was around 80%; however, in 
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the mid 1900s S. aureus infections began to be treated with penicillin.
17 
This helped 
to lower the mortality rate for infected patients. Resistance to penicillin emerged in 
1942 due to the acquisition of a plasmid that encoded a penicillin-hydrolyzing 
enzyme (penicillinase) and in only 18 years 80% of S. aureus strains were 
unaffected by the drug.
17,18,19 However, new generations of modified beta lactam 
antibiotics were briefly effective against S. aureus until 1961.
18,20,21,22 
 In 1961, just 
two years after methicillin was introduced, which is a semisynthetic form of 
penicillin, S. aureus strains emerged that were resistant to both methicillin and beta 
lactam antibiotics in general due to their acquisition of the mecA gene.
17,18
S. aureus 
strains have even developed resistance to other antibiotics like vancomycin if they 
harbor the vanA gene, making this pathogen one of the most difficult to treat, 
particularly in clinical settings where it rapidly evolves and is easily spread.
 18,23,24  
 
 
1.3 The mecA gene 
The existence of methicillin resistant S. aureus (MRSA) has placed a 
remarkable burden on the public health care system, where accurate molecular 
characterization is crucial for infection control and surveillance of the bacteria.25 
MRSA can be characterized by a genetic element, known as staphylococcal cassette 
chromosome mec (SCCmec) that is indicated by roman numerals I to XIII.25,26,27 The 
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SCCmec harbors the gene responsible for methicillin resistance, mecA, and the ccr 
gene complex responsible for genetic mobility.
26
 The mecA gene encodes a 
penicillin-binding protein (PBP) 2A or PBP2’. Since β-lactam antibiotics (like 
penicillin, or methicillin which is a semisynthetic derivative of penicillin) cannot  
bind to PBP2’, synthesis of peptidoglycan layer and cell wall synthesis are able to 
continue.26,27,28 
In 2011 it was reported that MRSA was capable of encoding a divergent 
mecA gene. This homologue known as mecC, previously known as mecALGA251, has 
the potential to be misdiagnosed as methicillin sensitive S. aureus, complicating 
patient management as well as MRSA surveillance.
28  
1.4 Community and Hospital Acquired 
During the late 1900’s two different populations of MRSA began to emerge, 
known as hospital acquired (HA) and community acquired (CA).29 HA-MRSA is 
usually associated with people who have had frequent or recent contact with 
healthcare facilities within the past year, or have recently undergone an invasive 
medical procedure.29,30,31 HA-MRSA is identified as types I, II, and III. It is a serious 
infection resistant to multiple drugs and infections occur at sites including the 
blood, skin, and lungs.29,32 CA-MRSA is associated with people who have not been in 
the healthcare facility or had a medical procedure within the past year. CA-MRSA 
typically consists of skin and soft tissue infections and is identified as types IV and 
 15 
V MRSA.33 While SCCmecA typing helps us to differentiate CA vs. HA, determining 
the true origin of each MRSA type is problematic. In recent years, researchers have 
been able to identify HA-MRSA in the community and vice versa blurring the line 
between HA and CA.34 The HA-MRSA could be evolving in healthcare facilities or 
could be brought into healthcare facilities by patients, visitors, etc.34  
 
 
 
 
 
Chapter 2 
Materials and Methodology 
2.1 Sample Collections 
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 Dr. Spratt and his student research assistants, including Colin Smith, worked 
with staff at Erlanger hospital to coordinate times to sample the NICU and PICU 
where they would swab various areas of the environment. These areas included 
stethoscopes, bed handles, bath basins, equipment drawers, computers, air ducts, 
floors, etc. Thermo Fisher Scientific sterile transport swabs with liquid Stuart’s 
medium were used to collect these samples. All swabs were placed on ice 
immediately after being collected. Patient samples were provided directly from the 
medical technology lab at Erlanger. Other than the fact that these samples came 
from patients in the NICU, we are unsure of the process used by the medical 
technology lab to obtain and classify these samples. 35,36 
 Figure 2.1. Sampling of Hospital Environment 
2.2 Lab Processing 
 Dr. Spratt and his team processed environmental swabs collected at 
Erlanger in a lab at UTC within two hours of collection. In the lab these swabs were 
used to inoculate onto six different bacteria growth mediums, five classified as 
selective & differential, and one non-specific growth medium: 
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• CHROM MRSA agar- selective and differential for methicillin resistant S. 
aureus (MRSA)37 
• Mannitol Salt Agar (MSA)- selective and differential for Staphylococci38 
• Eosin Methylene Blue (EMB)- selective and differential for Gram negative 
enterics39 
• Pseudomonas Isolation Agar (PsI)- selective and differential for 
Pseudomonas40 
• MacConkey’s Agar (MAC)- selective and differential for enterics41 
• Tryptic Soy Agar (TSA)- non-specific, supports growth of many different 
species42,43 
2.3 MRSA Characterization 
Environmental isolates from CHROM, MSA, and TSA were then line inoculated 
onto MSA agar that indicates mannitol fermentation by turning agar from a deep 
red color to a bright yellow.44 
Antibiotic disk diffusion tests were carried out on isolates showing positive for  
mannitol fermentation, to assess the strain’s resistance to four common beta-
lactam antibiotics: Penicillin, Amoxicillin, Oxacillin, and Vancomycin.45 Confirmed 
MRSA isolates were passed on to Dr. Giles and I for further characterization. 
 18 
  Figure 2.2. MSA testing for S. aureus characterization 
2.4 Genomic Extraction 
Upon receiving an 80% glycerol stock of confirmed MRSA isolates we grew 
overnight cultures to use for genomic extractions. Bacterial genetic DNA was then 
extracted using a Thermo Fisher Scientific kit and following the manufacturer’s 
instructions. Afterwards, quality and quantity of genomic DNA extracted was 
assessed using a Nanodrop spectrophotometer.46 
2.5 Multiplex Polymerase Chain Reaction 
Multiplex PCR was utilized for staphylococcal cassette chromosome mec 
typing with primers designed for SCCmec types, SCCmec subtypes, toxins, and the 
mecA gene.47,48,49,50,51 The PCR mixture included DNA, various primers, and master 
mix in a 25 µl final reaction (Figure 3) volume. Thermocycling condition were 94°C 
for 5 min, followed by 10 cycles of 94°C for 45 s, 65°C for 45 s, and 72°C for 90 s, 
followed by 25 cycles of 94°C for 45 s, 55°C for 45 s, and 72°C for 90 s, followed by 
72°C for 10 min.34 
 19 
  Figure 2.3. PCR Samples 
Primer  Oligonucleotide sequence   Amplicon Size (bp) 
mecA                    MecA147-F (5’- GTGAAGATATACCAAGTGATT-3′)   147 
          MecA147-R (5’-ATGCGCTATAGATTGAAAGGAT-3′) 
SCCmec Type I         Type I-F (5’-GCTTTAAAGAGTGTCGTTACAGG-3′)   613 
          Type 1-R (5’-GTTCTCTCATAGTATGACGTCC-3′) 
SCCmec Type II         Type II-F (5’-CGTTGAAGATGATGAAGCG-3′)   398 
          Type II-R (5’-CGAAATCAATGGTTAATGGACC-3′)   
SCCmec Type III         Type III-F (5’-CCATATTGTGTACGATGCG-3′)   280 
          Type III-R (5’-CCTTAGTTGTCGTAACAGATCG-3′) 
SCCmec Type IVa         Type IVa-F (5’-GCCTTATTCGAAGAAACCG-3’)   776 
          Type IVa-R (5’-CTACTCTTCTGAAAAGCGTCG-3′) 
SCCmec Type IVb         Type IVb-F (5’-TCTGGAATTACTTCAGCTGC-3′)   493 
          Type IVb-R (5’-AAACAATATTGCTCTCCCTC-3′)  
SCCmec Type IVc         Type IVc-F (5’-ACAATATTTGTATTATCGGAGAGC-3′)  200 
          Type IVc-R (5’-TTGGTATGAGGTATTGCTGG-3′) 
SCCmec Type IVd         Type IVd-F (5’-CTCAAAATACGGACCCCAATACA-3′)   881 
          Type IVd-R (5’-TGCTCCAGTAATTGCTAAAG-3′) 
SCCmec Type V         Type V-F (5’-GAACATTGTTACTTAAATGAGCG-3′)   325 
          Type V-R (5’-TGAAAGTTGTACCCTTGACACC-3′) 
Panton-Valentine         Luk-PV-1 (5’-ATCATTAGGTAAAATGTCTGGACATGATCCA-3′)  433 
Leukocidin (PVL)         Luk-PV-2 (5’-GCATCAAGTGTATTGGATAGCAAAAGC-3′) 
Toxic Shock          GTSSTR-1 (5’-ACCCCTGTTCCCTTATCATC-3′)   326 
Syndrome Toxin         GTSSTR-2 (5’-TTTTCAGTATTTGTAACGCC-3′) 
mecA          mecI-F (5’-CCCTTTTTATACAATCTCGTT-3’)   146 
          mecI-R (5’-ATATCATCTGCAGAATGGG) 
ccrAB          ccrAB-β2 (5’-ATTGCCTTGATAATAGCCITCT-3’) 
        ccrAB-α2 (5’-AACCTATATCATCAATCAGTACGT-3’)   700 
         ccrAB-α3 (5’-TAAAGGCATCAATGCACAAACACT-3’)   1,000 
        ccrAB-α4 (5’-AGCTCAAAAGCAAGCAATAGAAT-3’)   1,600 
ccrC        ccrC-F (5’-ATGAATTCAAAGAGCATGGC-3’)    336 
        ccrC-R (5’-GATTTAGAATTGTCGTGATTGC-3’) 
  
Table 2.1 List of primers used in this study.26,34 
2.6 Gel Electrophoresis 
 We made a 1.5% gel using the following procedure: put 0.6 g Agarose 
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powder into an Erlenmeyer flask, add 40 mL of TBE 1X, heat until the Agarose 
powder is dissolved, then add 2 µl of 10 mg/µl EtBr before pouring the mixture into 
the apparatus. After the gel in the apparatus has solidified, load the lanes with a 
100 bp ladder and PCR samples and run it at 120 V.52, 53, 54, 55, 56,57 
 
 
 
 
 
 
 
Chapter 3 
 21 
Results 
3.1 Nanodrop Spectrophotometer Results  
Upon completing our genomic extractions we utilized a nanodrop 
spectrophotometer to analyze the concentration and purity of our DNA. We found 
lysostaphin is a more efficient method of lysing S. aureus and ultimately produces a 
higher yield of DNA. A 260/280 ratio of ~1.8 is generally considered “pure” for 
DNA. A 260/230 ratio of ~2.0-2.2 is generally considered “pure” for nucleic acid. 
Patient Samples DNA 
Concentration 
(ng/μl) 
260/280 260/230 
1 10.1 2.88 8.99 
2 12.3 2.39 2.13 
3 19.0 2.25 1.91 
4 17.7 2.30 2.15 
5 30.9 2.30 2.24 
6 18.7 1.76 1.12 
7 6.50 3.24 3.16 
8 38.0 2.27 2.42 
Table 3.1. Results from nanodrop spectrophotometer after genomic extractions 
were completed on patient samples 1-8.  
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Table 3.2. Results from nanodrop spectrophotometer after genomic extractions 
were completed on patient samples 9-15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Samples DNA 
Concentration 
(ng/μl) 
260/280 260/230 
9 11.9 2.11 1.61 
10 557.1 1.34 0.64 
11 380.0 1.36 0.63 
12 419.0 1.28 0.62 
13 340.2 1.35 0.61 
14 656.0 1.35 0.61 
15 166.9 1.36 0.66 
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Patient Samples DNA 
Concentration 
(ng/μl) 
260/280 260/230 
18 361.8 1.96 1.20 
19 205.2 2.02 1.38 
20 481.1 1.60 0.80 
21 107.7 1.85 1.23 
22 164.3 1.97 1.43 
23 197.2 1.90 1.26 
24 1.61 1.68 0.93 
25 64.1 1.83 1.13 
26 153.9 1.32 0.71 
 
Table 3.3. Results from nanodrop spectrophotometer after genomic extractions 
were completed on patient samples 18-26 
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Environmental 
Samples 
DNA 
Concentration 
(ng/μl) 
260/280 260/230 
1c 123.1 1.94 1.67 
2c 340.7 2.00 1.19 
3c 137.9 1.94 1.12 
4c 53.0 2.00 1.26 
5c 384.6 2.00 1.15 
6c 289.3 2.02 1.23 
7c 112.4 1.94 1.09 
8c 60.6 2.00 1.33 
 
Table 3.4. Results from nanodrop spectrophotometer after genomic extractions 
were completed on environmental samples 1c-8c. 
 
Control Samples DNA 
Concentration 
(ng/μl) 
260/280 260/230 
BAA-41 120.7 1.85 1.24 
BAA-2094 93.5 1.68 0.91 
33592 73.5 1.78 1.18 
 
Table 3.5. Results from nanodrop spectrophotometer after genomic extractions 
were completed on control samples. 
 
 
 
 
 
3.2 Multiplex PCR Characterization of Patient 
Samples 
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 Initially observing patient samples 1-8, which were all labeled as MRSA by 
Erlanger hospital, 4 samples were not positive for the mecA gene that is indicative 
of MRSA (Figure 3.6), samples 2, 4, 6, and 8. We repeated the multiplex PCR run 
and gel with the same primers to confirm these 4 samples were negative for mecA. 
In this run only 2 samples, samples 4 and 8, were negative for the mecA gene 
(Figure 3.7). Diving into the literature for answers we found there is a divergent 
mecA gene known as mecLGA251, also referred to as mecC. After finding this out, we 
purchased the appropriate primers and tested samples 1-8 for mecLGA251, but 
samples 4 and 8 were negative for mecA and mecLGA251 (Figure 3.8). Due to this we 
did not believe patient samples 4 and 8 were MRSA, but suspected they were MSSA.  
 
 
 
 
 
 
Figure 3.1. Gel of patient samples 1-8 
from January 18th, 2017. Primers used are 
as follows: type I, II, III, IVa, IVb, IVc, IVd, V 
and mecA1417. The mecA gene is positive 
for samples 1, 3, 5, and 7. The mecA gene is 
negative for samples 2, 4, 6, and 8. 
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Figure 3.2. Gel of patient samples 1-8 from January 20th, 2017. Primers used are as 
follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is positive 
for samples 1, 2, 3, 5, 6, and 7. The mecA gene is negative for samples 4 and 8. In 
patient samples 2, 3, and 5 a strong band is seen at ~900 bp, indicating type IVd. In 
patient sample 6 there is a strong band at ~400 bp, indicating type II. 
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Figure 3.3. Gel of patient samples 1-8 from November 6th, 2017. Primers used are 
as follows: type I, II, III, IVa, IVb, IVc, IVd, V  mecA1417, and mecLGA251. The mecA 
gene is positive for samples 1, 2, 3, 5, 6, and 7. The mecA and mecLGA251 gene is 
negative for patient samples 4 and 8. In patient sample 6 there is a strong band at 
~400 bp, indicating type II. 
 
 
 As far as SCCmec types, throughout these 3 Multiplex PCR runs and gels we 
identified patient samples 2, 3, and 5 to be positive for type IVd and patient sample 
6 to be positive for type II (Figures 3.1, 3.2, 3.3).  
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 After characterizing patient samples 1-8, we moved on to samples 9-15. 
Samples 9-13 were labeled as MRSA and samples 14 and 15 were labeled MSSA by 
Erlanger hospital. In our first gel our results were what we expected them to be, the 
mecA gene was positive for samples 9-13 and negative for samples 14 and 15 
(Figure 3.4). However, there were no types observed. We believed this was 
possibly due to a lower quality gel imager and decided to repeat the run. Our 
findings regarding the mecA gene were consistent, but we observed type IVa in 
sample 11 and type II in sample 12 (Figure 3.5) on our second run. To confirm 
these findings an identical run was completed a third time. Our findings were 
consistent with what was found in our second run, but additionally sample 10 was 
positive for IVd (Figure 3.6). 
 
 
 
 
 
Figure 3.4. Gel of patient 
samples 9-15 from 
February 10th, 2017. 
Primers used are as 
follows: type I, II, III, IVa, 
IVb, IVc, IVd, V and 
mecA1417. The mecA gene 
is positive for samples 9, 
10, 11, 12, and 13. The 
mecA gene is negative for 
samples 14 and 15. 
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Figure 3.5. Gel of patient samples 9-15 from February 20th, 2017. Primers used are 
as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is 
positive for samples 9, 10, 11, 12, and 13. The mecA gene is negative for samples 14 
and 15. In patient sample 11 a strong band is seen at ~800 bp, indicating type IVa. 
In patient sample 12 a strong band is present at ~400 bp, indicating type II. 
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Figure 3.6. Gel of patient samples 9-15 from February 25th, 2017. Primers used are 
as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is 
positive for samples 9, 10, 11, 12, and 13. The mecA gene is negative for samples 14 
and 15. In patient sample 10 a strong band is seen at ~900 bp, indicating type IVd. 
In patient sample 11 a strong band is seen at ~800 bp, indicating type IVa. In 
patient sample 12 a strong band is present at ~400 bp, indicating type II. 
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 Although patient samples 14 and 15 were labeled as MSSA, not MRSA, by 
Erlanger hospital we wanted to confirm that they were not MRSA. Testing for the 
mecA and mecLGA251 would allow us to confirm this. Samples 14 and 15 tested 
negative for both mecA and mecLGA251, from this we determined they were in fact 
MSSA (Figure 3.12).  We also streaked patient samples 14 and 15 on CHROM MRSA 
agar, since it is a good indicator of MRSA with the mecA gene (Section 3.5). 
 
 
Figure 3.7. Gel of patient samples 9-15 from November 8th, 2017. Primers used are 
as follows: type I, II, III, IVa, IVb, IVc, IVd, V  mecA1417, and mecLGA251. The mecA 
gene is positive for samples 9, 10, 11, 12, and 13. The mecA and mecLGA251 gene is 
negative for patient samples 14 and 15. In patient sample 12 there is a strong band 
at ~400 bp, indicating type II. 
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 We completed a large gel consisting of patient samples 1-15. Samples 4, 8, 
14, and 15 were negative for mecA, which was expected. We tested positive for 
types II and IVd, but did not test positive for IVa. This could have been due to 
various reasons (Figure 3.8). 
 
 
 
Figure 3.8. Gel of patient samples 1-15 from February 22nd, 2017. Primers used are 
as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is 
positive for samples all samples except 4, 8, 14, and 15. In patient samples 2, 3, and 
5 a strong band is present at ~880 bp, indicating type IVd. In patient samples 6 and 
12 a strong band is present at ~400 bp, indicating type II. 
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In December 2017 we received ~50 new patient samples. After preforming 
genomic extractions on our new samples we were able to run multiplex PCR and 
gels on them. We tested patient samples 18-25 with our standard set of primers 
(mecA1417, types I-IVd), but left out type V (~325 bp) so we could observe if TSST 
(Toxic Shock Syndrome Toxin, a virulence factor) was present (~326 bp). The two 
are too close in size to differentiate if a sample was to test positive. All samples 
were positive for mecA. No samples were positive for TSST (Figure 3.9). 
                       
 
Figure 3.9. Gel of patient samples 18-25 from February 16th, 2018. Primers used 
are as follows: type I, II, III, IVa, IVb, IVc, IVd, mecA1417, and TSST. The mecA gene 
is positive for samples. No samples were positive for TSST.  
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 We repeated this run, but used type V instead of the TSST primer. Our 
results regarding mecA were consistent, but we also had patient samples 22 and 23 
test positive for type III at ~280 bp. No samples were positive for type V (Figure 
3.10). 
 
 
 
 
Figure 3.10. Gel of patient samples 18-25 from February 23rd, 2017. Primers used 
are as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is 
positive for all samples. samples 22 and 23 a band is present at ~280, indicating 
type III.  
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3.3 Multiplex PCR Characterization of 
Environmental Samples 
 
Environmental samples, 1c-8c, were observed using 2 sets of primers. In 
lanes 1-8 we used our standard set of primers (mecA1417, types I-V) and in lanes 9-
16 we used unique mix found in a different paper. In lanes 1-8 there mecA gene was 
positive for samples 4-8, but we decided to run another gel in hopes to see stronger 
bands in samples 1-3. Additionally, sample 4 was positive for type IVa (Figure 
3.11). 
 
  
 
  
Figure 3.11. Gel of environmental 
samples 1c-8c from March 29th, 
2017. Two sets of primers were 
used. In lanes 1-8 the primers used 
are as follows: type I, II, III, IVa, IVb, 
IVc, IVd, V and mecA1417. In lanes 
9-16 the primers used are as 
follows: mecA1417, mecI, ISI272, 
ccrAB-α2, ccrAB-α3, ccrAB-α4, 
ccrAB-β2, and ccrC. In 
environmental sample 4 a strong 
band is seen at ~800 bp, indicating 
type IVa. In lanes 9, 12, 15, and 16 
bands are present at ~146 bp, 
indicating mecA. In lanes 9, 12,14, 
and 16 bands are present at~336 
bp, indicating ccrC gene which is 
harbored by MRSA. 26,34 
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A second gel was run on environmental samples 1c-8c again, this time only 
using 1 set of primers (mecA1417, types I-V). Samples 1c and 4c-8c were positive 
for mecA. Samples 2c and 3c were negative for mecA despite being previously 
determined as MRSA by Dr. Spratt’s lab. Sample 4c was positive for type IVa. 
Sample 6c was positive for type III. Sample 8c is positive type V (Figure 3.12).  
 
 
Figure 3.12. Gel of environmental samples 1c-8c from September 22nd, 2017. 
Primers used are as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. In 
environmental sample 4c a strong band is present at ~800 bp, indicating type IVa. 
In environmental sample 6c a strong band is present at ~280 bp, indicating type III. 
In environmental sample 8c a strong band is present at ~325 indicating type V. 
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 Since environmental samples 2c and 3c were expected to be MRSA, we did a 
third run suspecting the two samples would be positive for mecA. Additionally, we 
used PVL (Panton-Valentine Leukocidin, a virulence factor,~433 bp) and TSST 
(~326 bp) primers in place of types IVb (~493) and V (~325), respectively. The 
mecA gene was present in all samples. No samples were positive for PVL or TSST 
(Figure 3.13). 
   
 
Figure 3.13. Gel of environmental samples 1c-8c from December 2nd, 2017. 
Primers used are as follows: type I, II, III, IVa, IVc, IVd, mecA1417, PVL, and TSST. 
Type IVb and V were not tested for as their bp are too close in size to PVL and TSST 
to differentiate. No environmental samples tested positive for PVL or TSST.  
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3.4 Multiplex PCR Characterization of Control 
Samples 
Later into the study, we purchased control samples of MRSA from the 
American Type Culture Collection to ensure our primers were operating properly. 
We purchased BAA-41, BAA-2094, and 33592, which were controls for types II, III, 
and V, respectively.  We ran a PCR and gel with primers for type II, III, V, and 
mecA1417. BAA-41 and BAA-2094 did not test positive for their expected types. 
This could be due to human error and will be repeated at a later date (Figure 3.14). 
                               
 
Figure 3.14. Gel of control samples (BAA-41, BAA-2094, and 33592) from March 
6th, 2018. Primers used are as follows: type II, III, V, and mecA1417. The mecA gene 
is positive for samples BAA-2094 and 33592. Sample 33592 was positive for type V, 
which was expected. BAA-41 and BAA-2094 were negative for, respectively, type II 
and III, which was not expected. 
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3.5 Plates 
 After repeated multiplex PCR and gels to identify mecA or mecLGA251 in 
patient samples 4 and 8 were consistently negative we decided to streak plates and 
compare them to known MSSA samples, samples 14 and 15. Working with Colin 
Smith, utilizing visual examination of the plates combined with repeated negative 
results from gels we determined samples 4 and 8 were also MSSA, not MRSA. 
                                      
 
 Patient Sample 4           Patient Sample 8 
 
 
                                      
 
 Patient Sample 14     Patient Sample 15 
 
 
Figure 3.15. Patient samples 4, 8, 14, and 15 streaked onto agar plates were 
determined to be methicillin-sensitive S. aureus.  
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3.6 Pie Graphs 
 
Figure 3.16. Comparison of MRSA and MSSA patient isolates. 
 
 
 
 
 
 
 
Figure 3.17. Types found within MRSA patient isolates.  
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Figure 3.18. Types found within MRSA patient isolates. 
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Chapter 4 
 
Discussion and Future Direction 
 
 Methicillin resistant S. aureus is a major public health concern.  A patient 
infected with MRSA can experience many complications, with some even being life 
threatening. Due to this bacteria’s severity, it is imperative for researchers to have a 
thorough understanding of how it is transferred, different types present, if it is 
carrying virulence factors, and so forth.58 
 We had multiple goals in this research: to confirm if isolates were MRSA or 
not, identify if there was any correlation between patient and environmental 
isolates, and to determine if any isolates had virulence factors.  
 Beginning with our patient samples we used a standard set of primers 
consisting of the following: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The 
mecA1417 gene is indicative of MRSA allowing us to confirm if isolates were MRSA 
or not. Patient samples 4, 8, 14, and 15 were all negative for mecA1417. We were 
not surprised samples 14 and 15 were negative as they were labeled methicillin-
sensitive, not resistant, S. aureus (MSSA) when we received them. However, patient 
samples 4 and 8 were labeled MRSA, which prompted us to rerun our PCR and gel. 
Again we had negative results for mecA1417 with patient samples 4 and 8, but it 
was possible that these samples had the divergent gene for mecA, known as 
mecALGA251.  Patient samples 4 and 8 also tested negative for mecALGA251 leading us to 
believe they were not MRSA, but instead MSSA. We streaked plates with our two 
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known methicillin-sensitive samples, 14 and 15, and what we believed to be 
methicillin-sensitive samples, 4 and 8. After allowing these samples to grow and 
upon visual examination it was determined samples 4, 8, 14, and 15 were MSSA.  
 Our patient samples exhibited various types of MRSA. Patient samples 2, 3, 
5, and 10 were positive for type IVd. Patient samples 6 and 12 were positive for 
type II. Patient sample 11 was positive for type IVa. Patient samples 22 and 23 were 
positive for type III. Patient samples 16 and 17 were contaminated during our 
process and no longer viable for observation. The remaining MRSA patient samples: 
1, 9, 18, 19, 20, 21, 24, and 25 were not typed. Due to time constraints, we only 
observed types I-V, but there is typing available up to type X.59,60 
 Our 8 environmental samples were all positive for mecA1417. 
Environmental sample 4 was positive for type IVa. Environmental sample 6 was 
positive for type III. Environmental sample 8 was positive for type V.  The 
remaining MRSA environmental samples: 1, 2, 3, 5, and 7 were not typed, but may 
be types VI-X that were not tested for. Types III and IVa were present in both 
patient and environmental samples. This could indicate transmission from various 
objects or surfaces to patients.60  
Our most common type of MRSA found was type IV. Type IV MRSA has also 
been found in other countries such as Brazil, Denmark.61,62  Additionally in other 
studies where U.S. isolates were observed, type IV isolates were a common 
finding.63 
The limiting factor to this study was the small amount of environmental 
samples available. If there were a larger amount of environmental samples it is 
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possible that additional correlations would have been found between patient and 
environmental samples.  
 In future studies researchers should examine the 42 new patient samples we 
have received from Erlanger hospital’s NICU and PICU. These should be examined 
for mecA1417, mecALGA251, and type I-X.  Additionally, more environmental samples 
should be obtained with the known location (stethoscope, crib, air duct, floors, etc.) 
in order to observe more detailed correlations between patient and environmental 
samples, as well as identify if certain locations have higher incidences of a certain 
type or virulence factors than others. 
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